Teva: Biosimilars In The US Will Become Like Complex Generics
North America Head Brendan O’Grady Discusses Teva’s Biosimilar Expectations
With a couple of major partnerships and a stable of internal projects, Teva expects to play a role in the “majority of meaningful US biosimilar launches in the next five-to-eight years,” executive vice-president for North America commercial Brendan O’Grady told Generics Bulletin in an exclusive interview.
